Spruce Biosciences (SPRB) Liabilities and Shareholders Equity (2019 - 2026)

Spruce Biosciences (SPRB) has reported Liabilities and Shareholders Equity for 8 consecutive years, with $56.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 77.47% year-over-year to $56.2 million; the TTM figure through Mar 2026 stood at $146.3 million (down 32.72% YoY), while the FY2025 annual figure was $53.0 million, up 17.28% from the prior year.
• Liabilities and Shareholders Equity grew to $56.2 million in Q1 2026 per SPRB's latest filing, from $53.0 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $139.1 million in Q1 2023 and bottomed at $15.3 million in Q3 2025.
• Historically, Liabilities and Shareholders Equity has averaged $78.5 million across 5 years, with a median of $85.6 million in 2022.
• Annual changes were most pronounced in 2025 — Liabilities and Shareholders Equity tumbled 76.48% — and 2026, when it surged 77.47%.
• Spruce Biosciences' Liabilities and Shareholders Equity stood at $85.6 million in 2022, then advanced by 21.36% to $103.9 million in 2023, then sank by 56.51% to $45.2 million in 2024, then rose by 17.28% to $53.0 million in 2025, then grew by 5.93% to $56.2 million in 2026.
• Business Quant data shows SPRB's Liabilities and Shareholders Equity at $56.2 million in Q1 2026, $53.0 million in Q4 2025, and $15.3 million in Q3 2025.